Developing a maternal vaccine against Group B Streptococcus
Subheadings
At a glance
At a glance Year of investment: 2022 Sector: Vaccines Stage: Clinical development Headquarters: Denmark CEO: Per Fischer Trill Impact board representative: Bita Sehat
MinervaX is a Danish biotech company developing a maternal vaccine to prevent life-threatening infections in newborns. The vaccine seeks to avoid Group B streptococcus (“GBS”) bacteria responsible for infant deaths, stillbirths, and severe disabilities in children globally.
MinervaX's solution
Social/Environmental challenge
GBS bacteria the leading cause of life-threatening bacterial infection in newborns, causing infant mortality and stillbirth as well as severe pregnancy complications for the mother
Disproportionately affects low- and middle-income countries
Increasing AMR: Prophylactic antibiotics treatment offered to women at risk, driving antimicrobial resistance
SDG Contribution
SDG #3.1 – Reduce maternal mortality Potential contribution: Reduce preventable deaths caused by GBS infection in pregnant mothers
SDG # 3.2: End all preventable deaths under 5 years of age Potential contribution: Reduce preventable deaths caused by GBS infection in newborns
SDG #3.3 – Fighting communicable diseases Potential contribution: Reduction of GBS infections and combating antimicrobial resistance
SDG #3.b – support R&D, and universal access to affordable vaccines and medicines Potential contribution: Affordable vaccine that allows for global distribution through established procurement and distribution mechanisms
This website uses cookies to improve your user experience, to provide a basis for improvement and further development of the website and to be able to direct more relevant offers to you.
Feel free to read ours privacy policy. If you agree to our use, choose Accept all. If you want to change your choice afterwards, you will find that option at the bottom of the page.